Consun Pharmaceutical Group Limited released its Monthly Return for Equity Issuer for the period ended 31 August 2026, confirming that the company’s share capital structure remained unchanged throughout the month.
The authorised share capital stood at 5.00 billion ordinary shares with a par value of HKD 0.10, equivalent to HKD 500.00 million. No increase or decrease in authorised capital was recorded during August.
Issued share capital was steady at 839.05 million ordinary shares (excluding 2.50 million treasury shares), leaving the total number of issued shares unchanged at 841.55 million. There were no issuances, cancellations, or share buy-backs in the period.
Consun Pharma affirmed compliance with the Main Board’s minimum public-float requirement of 25%, indicating that its free-float level remained sufficient as at 31 August 2026.
Regarding employee incentives, 7.07 million options under the 2013 Share Option Scheme remained outstanding, with no exercises or cancellations during the month. The 2024 Share Option Scheme currently has no outstanding options, though it allows for up to 84.28 million new shares to be issued in future grants. No funds were raised from option exercises in August.
The company reported no outstanding warrants, convertible securities, or other equity-linked instruments, and no additional share movements or treasury share transactions occurred.
The disclosure was submitted by Company Secretary Gao Haien on 1 September 2026, confirming adherence to all relevant Hong Kong Stock Exchange listing rules and regulatory requirements.
Comments